Lowering Tacrolimus for Low-Risk Kidney Transplant Patients
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received your first-ever kidney transplant from a living donor, a brain-dead donor, or a controlled donation-after-circulatory-death donor.
- Your blood type (ABO) is compatible with the donor's blood type.
- One year after transplant, your immune system didn't show signs of attacking the kidney (low cPRA, no DSA, and ≤14 eplet mismatches).
- A year after transplant, a kidney biopsy showed it's healthy or has only mild scarring (IFTA 1-2).
- You're taking tacrolimus (Prograf® or Advagraf®) plus mycophenolate, and possibly a steroid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study observes older kidney transplant patients (65+) who take a specific anti-rejection drug called tacrolimus once a day. It looks at their long-term outcomes to help improve care for people in this age group.
Hear when a new Organ Grafts trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.